US · Healthcare · Biotechnology
EPS came in at -0.17 against a street estimate of -0.11 — a miss of 54.5%.
Analysts rate Century Therapeutics Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $4.75.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 9.80% |
| TCG Crossover Management, LLC | 9.80% |
| Versant Venture Management LLC | 6.72% |
| Deep Track Capital, LP | 5.23% |
| VR Adviser, LLC | 4.80% |
| COMMODORE CAPITAL LP | 4.80% |
| RTW INVESTMENTS, LLC | 4.80% |
| Point72 Asset Management, L.P. | 3.29% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Century Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.